The Fort Worth Press - Once-taboo ketamine booms for US at-home mental care

USD -
AED 3.672931
AFN 67.93001
ALL 93.193946
AMD 386.923413
ANG 1.801781
AOA 912.999671
ARS 997.103104
AUD 1.547341
AWG 1.8025
AZN 1.703673
BAM 1.857034
BBD 2.018544
BDT 119.466191
BGN 1.854223
BHD 0.376748
BIF 2951.893591
BMD 1
BND 1.345309
BOB 6.907618
BRL 5.789698
BSD 0.999734
BTN 84.379973
BWP 13.7232
BYN 3.271695
BYR 19600
BZD 2.015126
CAD 1.406455
CDF 2866.00005
CHF 0.88937
CLF 0.035356
CLP 975.579787
CNY 7.23401
CNH 7.243415
COP 4481.75
CRC 510.622137
CUC 1
CUP 26.5
CVE 104.696706
CZK 23.993899
DJF 178.02275
DKK 7.07656
DOP 60.463063
DZD 133.904275
EGP 49.549401
ERN 15
ETB 123.922406
EUR 0.94865
FJD 2.27485
FKP 0.789317
GBP 0.78905
GEL 2.725033
GGP 0.789317
GHS 16.070301
GIP 0.789317
GMD 71.000115
GNF 8615.901679
GTQ 7.720428
GYD 209.156036
HKD 7.782685
HNL 25.243548
HRK 7.133259
HTG 131.35034
HUF 385.46702
IDR 15907.1
ILS 3.741525
IMP 0.789317
INR 84.45765
IQD 1309.646453
IRR 42104.999694
ISK 138.220286
JEP 0.789317
JMD 158.263545
JOD 0.709099
JPY 156.4735
KES 129.219667
KGS 86.376503
KHR 4060.610088
KMF 466.498376
KPW 899.999621
KRW 1398.579954
KWD 0.30758
KYD 0.833092
KZT 495.639418
LAK 21961.953503
LBP 89524.727375
LKR 292.075941
LRD 184.450901
LSL 18.299159
LTL 2.95274
LVL 0.60489
LYD 4.883306
MAD 9.985045
MDL 18.109829
MGA 4683.909683
MKD 58.422784
MMK 3247.960992
MNT 3397.999946
MOP 8.014356
MRU 39.742695
MUR 47.149715
MVR 15.460342
MWK 1733.51184
MXN 20.47466
MYR 4.478975
MZN 63.849636
NAD 18.299159
NGN 1679.689752
NIO 36.789837
NOK 11.14296
NPR 135.008261
NZD 1.706994
OMR 0.386496
PAB 0.999729
PEN 3.809397
PGK 3.960922
PHP 58.834983
PKR 277.672857
PLN 4.10015
PYG 7807.745078
QAR 3.644486
RON 4.720201
RSD 111.069126
RUB 99.474049
RWF 1372.604873
SAR 3.756031
SBD 8.383384
SCR 13.614088
SDG 601.504102
SEK 10.989285
SGD 1.3435
SHP 0.789317
SLE 22.697547
SLL 20969.504736
SOS 571.317344
SRD 35.356498
STD 20697.981008
SVC 8.747751
SYP 2512.529858
SZL 18.306462
THB 34.936501
TJS 10.657058
TMT 3.5
TND 3.157485
TOP 2.342097
TRY 34.421302
TTD 6.787981
TWD 32.514983
TZS 2660.000162
UAH 41.213563
UGX 3668.871091
UYU 42.471372
UZS 12804.018287
VES 45.450249
VND 25397.5
VUV 118.722009
WST 2.791591
XAF 622.834653
XAG 0.033047
XAU 0.000391
XCD 2.70255
XDR 0.753148
XOF 622.834653
XPF 113.237465
YER 249.849915
ZAR 18.29015
ZMK 9001.200034
ZMW 27.416836
ZWL 321.999592
  • RBGPF

    61.8400

    61.84

    +100%

  • CMSC

    -0.0600

    24.55

    -0.24%

  • RYCEF

    -0.3200

    6.79

    -4.71%

  • AZN

    -0.2500

    65.04

    -0.38%

  • VOD

    -0.0700

    8.68

    -0.81%

  • NGG

    0.2500

    62.37

    +0.4%

  • RELX

    -0.1700

    45.95

    -0.37%

  • BTI

    0.0700

    35.49

    +0.2%

  • RIO

    -0.1900

    60.43

    -0.31%

  • GSK

    -0.7200

    34.39

    -2.09%

  • CMSD

    -0.0050

    24.725

    -0.02%

  • BP

    0.4800

    29.05

    +1.65%

  • BCC

    -2.2000

    140.35

    -1.57%

  • BCE

    -0.3700

    26.84

    -1.38%

  • SCS

    -0.1000

    13.27

    -0.75%

  • JRI

    -0.0300

    13.21

    -0.23%

Once-taboo ketamine booms for US at-home mental care
Once-taboo ketamine booms for US at-home mental care

Once-taboo ketamine booms for US at-home mental care

Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.

Text size:

A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.

Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.

"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."

Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.

It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.

In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.

- Ketamine 'babysitter' -

Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.

An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.

Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.

"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.

For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.

Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.

"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.

Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.

- 'Change your life' -

US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.

Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.

He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.

"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.

Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.

Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.

Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.

"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.

S.Weaver--TFWP